Alvine Pharmaceuticals, Inc., with headquarters located in San Carlos, California, announced on 9.22.11 that data from their Phase 2a clinical trial of ALV003 in celiac disease patients will be presented at the 19th United European Gastroenterology Week (UEGW) in Stockholm, Sweden. The data will be presented on Monday, 24 October by Markku Maki, M.D., Ph.D., Chair, Professor of Pediatrics at the University of Tampere and Tampere University Hospital in Finland at the Stockholm event.
ALV003 is an “interventional” drug consisting of proteases which would “degrade” gluten into fragments which could then be tolerated by Celiacs. The drug would be taken orally.
Visit http://www.alvinepharma.com/alv003/ to learn more about Alvine and their development of ALV003.
Could this be the first treatment method for Celiacs! Let’s hope.
(To learn more about the upcoming United European Gastroenterology Week in Stockholm, visit http://www.uegf.org/uegw/upcoming_congress.php?navId=21)
